Pharmafile Logo
Pharmafocus logo
Advanced Search

Remicade

Showing 15 posts of 31 posts found.

FDA advisory committee recommends approval of Remicade biosimilar

February 10, 2016
Research and Development, Sales and Marketing FDA, Pfizer, Remicade, biosimilar, celltrion

An FDA advisory panel yesterday voted overwhelmingly in favour of approving CT-P13- Celltrion’s biosimilar version of Johnson&Johnson’s blockbuster arthritis drug …

News
fda

FDA set to approve Remicade biosimilar

February 9, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Remicade, biosimilars, remsima

An FDA committee has had some positive words for Celltrion’s biosimilar candidate to Janssen/MSD’s Remicade (infliximab), concluding that the copycat biologic …

News
Merck image

Merck sales fall in Q1 despite new product lifts

April 29, 2015
Sales and Marketing Merck, Q1, Remicade

Merck’s sales were down in the first quarter of 2015 thanks to its consumer care divestment and increasing competition for …

News

NICE recommends hep C and bowel treatments

February 26, 2015
Sales and Marketing AbbVie, Humira, J&J, JJ, Janssen, Merck, Remicade, Simponi, olysio

Three drugs to treat chronic bowel condition ulcerative colitis and one for hepatitis C will be funded by the NHS …

News
Napp image

Napp launches biosimilar in UK

February 25, 2015
Research and Development, Sales and Marketing Hospira, Napp, Remicade, anti-TNF biologic, biosimilar, infliximab, remsima

Napp Pharmaceuticals has launched its own biosimilar version of an anti-TNF biologic in Europe paving the way for patient access …

News
Hospira image

Hospira launches biosimilar monoclonal antibody

February 16, 2015
Research and Development, Sales and Marketing MSD, Merck, Remicade, biosimilar. hospira, inflectra, infliximab

Hospira has won the race to become the first company to launch a biosimilar version of an anti-TNF biologic, after …

News
J&J image

Olysio and Xarelto boost J&J’s Q4

January 21, 2015
Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four

Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …

News
Ranbaxy image

Ranbaxy launches J&J biosimilar in India

December 5, 2014
Manufacturing and Production, Sales and Marketing CHMP, FDA, India, J&J, JJ, Ranbaxy, Remicade, nlem, nppa

Ranbaxy has launched the first biosimilar of Johnson & Johnson’s Remicade (infliximab) in India, marking the firm’s entry into monoclonal …

News
J&J image

J&J profits up amid drug gains

January 23, 2014
Sales and Marketing FDA, J&J, JJ, Remicade, Zytiga, olysio, q4

Johnson & Johnson’s sales in the fourth quarter of 2013 rose 4.5% compared to the same period in the previous …

News
Hospira image

Hospira’s Inflectra approved in Europe

September 10, 2013
Research and Development, Sales and Marketing Hospira, Janssen, Remicade, biosimilars, inflectra

Hospira has been the first firm to meet the European Commission’s approval for a biosimilar monoclonal antibody therapy with its …

News
Remicade image

Remicade copies set for European entry

July 1, 2013
Sales and Marketing CHMP, Hospira, Janssen, Remicade, arthritis, biosimilar

Janssen’s Remicade could soon come under generic pressure after a landmark recommendation by the CHMP. South Korean biotech Celltrion and …

News
Arthritis drug Remicade

J&J and Merck reach compromise on arthritis drug rights

April 19, 2011
Sales and Marketing Johnson & Johnson, Merck & Co, Remicade, Simponi

Johnson & Johnson and Merck & Co have agreed to split the regional rights to arthritis drugs Remicade and Simponi …

News
Abbott's Humira (adalimumab)

Abbott wins $1.7bn Humira case

February 24, 2011
Sales and Marketing Abbott, Abbott Laboratories, Centocor, Johnson and Johnson, Remicade, Simponi, TNF, golimumab, infliximab, rheumatoid arthritis

Abbott has been saved from paying Johnson & Johnson $1.7 billion after a US appeals court quashed a patent dispute …

News

J&J posts negative growth as pharma sales stall

January 26, 2011
Sales and Marketing 2010 pharma results, J&J, JJ, Johnson and Johnson, Remicade, Risperdal Consta

Falling fourth quarter sales of Risperdal Consta and Remicade capped a year to forget for Johnson and Johnson. The company’s …

News

J&J and Merck heading for showdown over drug rights

September 8, 2010
Sales and Marketing Johnson & Johnson, Merck, Remicade

Johnson & Johnson’s disagreement with Merck over rights to two arthritis drugs is set to come to a head in …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024